CoChat

Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology

Holubová, Martina, Hrubá, Lucie, Popelová, Andrea, Bencze, Michal, Pražienková, Veronika, Gengler, Simon, Kratochvílová, Helena, Haluzík, Martin, Železná, Blanka, Kuneš, Jaroslav, Hölscher, Christian, Maletínská, Lenka · 2019 · Neuropharmacology
Cited by 82

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

&NA; Obesity and type 2 diabetes mellitus (T2DM) are important risk factors for Alzheimer's disease (AD). Drugs originally developed for T2DM treatment, e.g., analog of glucagon‐like peptide 1 liraglutide, have shown neuroprotective effects in mouse models of AD. We previously examined the neuroprotective properties of palm11‐PrRP31, an anorexigenic and glucose‐lowering analog of prolactin‐releasing peptide, in a mouse model of AD‐like Tau pathology, THY‐Tau22 mice. Here, we demonstrate the neuroprotective effects of palm11‐PrRP31 in double transgenic APP/PS1 mice, a model of AD‐like &bgr;‐amyloid (A&bgr;) pathology. The 7‐8‐month‐old APP/PS1 male mice were subcutaneously injected with liraglutide or palm11‐PrRP31 for 2 months. Both the liraglutide and palm11‐PrRP31 treatments reduced the A&bgr; plaque load in the hippocampus. Palm11‐PrRP31 also significantly reduced hippocampal microgliosis, consistent with our observations of a reduced A&bgr; plaque load, and reduced cortical astrocytosis, similar to the treatment with liraglutide. Palm11‐PrRP31 also tended to increase neurogenesis, as indicated by the number of doublecortin‐positive cells in the hippocampus. After the treatment with both anorexigenic compounds, we observed a significant decrease in Tau phosphorylation at Thr231, one of the first epitopes phosphorylated in AD. This effect was probably caused by elevated activity of protein phosphatase 2A subunit C, the main Tau phosphatase. Both liraglutide and palm11‐PrRP31 reduced the levels of caspase 3, which has multiple roles in the pathogenesis of AD. Palm11‐PrRP31 increased protein levels of the pre‐synaptic marker synaptophysin, suggesting that palm11‐PrRP31 might help preserve synapses. These results indicate that palm11‐PrRP31 has promising potential for the treatment of neurodegenerative diseases. HIGHLIGHTSPalm11‐PrRP31 is an anorexigenic and glucose‐lowering analog of PrRP.Palm11‐PrRP31 treatment was neuroprotective in APP/PS1 mice, a model of amyloidosis.The treatment reduced &bgr;‐amyloid plaque load, microgliosis and astrogliosis.The treatment reduced Tau phosphorylation and tended to increase adult neurogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2018.11.002

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 82

Metadata

Authors
Holubová, M., Hrubá, L., Popelová, A., Bencze, M., Pražienková, V., Gengler, S., Kratochvílová, H., Haluzík, M., Železná, B., Kuneš, J., Hölscher, C., & Maletínská, L.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2019-01
Volume
144
Pages
377-387
ISSN
0028-3908 (ISSN-L)
OpenAlex
W2900189832
Cited by
82
References
10
FWCI
4.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology. https://app.cochat.ai/papers/10.1016/j.neuropharm.2018.11.002
The paper
Holubová, M., Hrubá, L., Popelová, A., Bencze, M., Pražienková, V., Gengler, S., Kratochvílová, H., Haluzík, M., Železná, B., Kuneš, J., Hölscher, C., & Maletínská, L. (2019). Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.11.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.